More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Regorafenib [BAY 73-4506]
Chemical Structure
Chemical Structure
Chemical Structure

Regorafenib [BAY 73-4506]

Research Use Only
AG-CR1-3623
AdipoGen Life Sciences
CAS Number755037-03-7
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight482.8
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Regorafenib [755037-03-7]
  • Delivery Days Customer
    10
  • CAS Number
    755037-03-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C21H15ClF4N4O3
  • Molecular Weight
    482.8
  • Scientific Description
    Chemical. CAS: 755037-03-7. Formula: C21H15ClF4N4O3. MW: 482.8. Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent. Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively. - Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent. Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively.
  • SMILES
    CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity: S.M. Wilhelm, et al.; Int. J. Cancer 129, 245 (2011)
  • Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors: G.D. Demetri; Semin. Oncol. 38, S10 (2011)
  • Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib: K.A. Lyseng-Williamson, et al.; BioDrugs 27, 525 (2013) (Review)
  • Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors: D.J. Crona, et al.; Ann. Pharmacother. 47, 1685 (2013) (Review)
  • Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer: R. Schmieder, et al.; Int. J. Cancer 135, 1487 (2014)
  • Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis: Z. Weng, et al.; Toxicology 327, 10 (2015)